story of the week
Outcomes Superior With Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JNCI Cancer Spectrum
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
JNCI Cancer Spectr 2020 Feb 01;4(1)pkz085, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, L Fehrenbacher, LA Mina, S Diab, NE Woodward, R Yerushalmi, A Goodwin, JL Blum, M Martin, RGW Quek, IC Tudor, H Bhattacharyya, E Gauthier, JK Litton, W EiermannFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.